1-[5-Amino-1-(chloromethyl)-1,2-dihydrobenzo[e]indol-3-yl]-3-(4-methoxyphenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 1-[5-Amino-1-(chloromethyl)-1,2-dihydrobenzo[e]indol-3-yl]-3-(4-methoxyphenyl)prop-2-en-1-one
• 化学式: C₂₃H₂₁ClN₂O₂
• 分子量: 392.885
• InChiKey: IMWKRMJFEUPBBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[5-Amino-1-(chloromethyl)-1,2-dihydrobenzo[e]indol-3-yl]-3-(4-methoxyphenyl)prop-2-en-1-one 在 吡啶 、 甲醇 、 Methoximagnesiumchlorid 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF GLUCURONIDE DRUG-LINKERS AND INTERMEDIATES THEREOF
  [FR] PROCÉDÉ DE PRÉPARATION DE LIEURS DE MÉDICAMENT, À BASE DE GLUCURONIDE, ET LEURS INTERMÉDIAIRES

  摘要：

  本发明提供了一种改进的制备具有β-葡聚糖醇可切割单元的药物连接剂的工艺，以及其中间体。

  公开号：

  WO2018175994A1

文献信息

• [EN] PROCESSES FOR PREPARING 3-SUBSTITUTED 1-(CHLOROMETHYL)-1,2-DIHYDRO-3H-[RING FUSED INDOL-5-YL(AMINE-DERIVED)] COMPOUNDS AND ANALOGUES THEREOF, AND TO PRODUCTS OBTAINED THEREFROM<br/>[FR] PROCEDE DE PREPARATION DE COMPOSES DE 3-SUBSTITUE 1-(CHLOROMETHYL)-1,2-DIHYDRO-3H [-5-YL A CYCLES FUSIONNES (DERIVES D'AMINE)] ET DE LEURS ANALOGUES, ET PRODUITS DERIVES
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2003097635A1

  公开（公告）日：2003-11-27

  The invention provides processes of preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl(amine-derived)] compounds of formula (I) and its analogues, or a physiologically functional derivative thereof, (I), wherein A and B together may represent a fused optionally substituted benzene, naphthalene, pyridine, furan or a pyrrole ring, where the optional substituents are represented by Y; X is halogen or OSO2R , and W is selected from NO2, NHOH, N(R3)2NHR3, NHCO2R3, N(phthaloyl) or NH2, or W is further selected from the group (a) , wherein J is selected from OH or R, and P is a group which is a substrate suitable for a nitroreductase or carboxypeptidase enzyme. The invention is also directed to the use of compounds of formula (I) prepared by the processes of the invention as cytotoxins for cancer therapy and as prodrugs for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT).

  该发明提供了制备公式（I）及其类似物的3-取代1-(氯甲基)-1,2-二氢-3H-[环融合吲哚-5-基（衍生自胺基）]化合物的过程，或其生理功能衍生物，其中A和B一起可以表示一个融合的可选取代苯、萘、吡啶、呋喃或吡咯环，其中可选取代基由Y表示；X为卤素或OSO2R，W从NO2、NHOH、N(R3)2NHR3、NHCO2R3、N(邻苯二甲酰基)或NH2中选择，或W进一步从群（a）中选择，其中J从OH或R中选择，P是适用于硝基还原酶或羧肽酶的底物基团。该发明还涉及通过该发明的过程制备的公式（I）化合物作为抗癌细胞毒素以及基因导向酶-前药疗法（GDEPT）和抗体导向酶-前药疗法（ADEPT）的前药的用途。
• Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom
  申请人：Denny Alexander William

  公开号：US20050148651A1

  公开（公告）日：2005-07-07

  The invention provides processes of preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl(amine-derived)] compounds of formula (I) and its analogues, or a physiologically functional derivative thereof, (I), wherein A and B together may represent a fused optionally substituted benezene, naphthalene, pyridine, furan or a pyrrole ring, where the optional substituents are represented by Y; X is halogen or OSO 2 R, and W is selected from NO 2 , NHOH, N(R 3 ) 2 NHR 3 , NHCO 2 R 3 , N(phthaloyl) or NH 2 , or W is further selected from the group (a), wherein J is selected from OH or R, and P is a group which is a substrate suitable for a nitroreductase or carboxypeptidase enzyme. The invention is also directed to the use of compounds of formula (I) prepared by the processes of the invention as cytotoxins for cancer therapy and as prodrugs for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT).

  本发明提供了制备式(I)及其类似物或其生理功能衍生物的3-取代-1-(氯甲基)-1,2-二氢-3H-[环融合吲哚-5-基(氨基衍生)]化合物的过程，其中A和B在一起可以表示为融合的可选取代苯、萘、吡啶、呋喃或吡咯环，其中可选的取代基由Y表示；X是卤素或OSO2R，W从NO2、NHOH、N(R3)2NHR3、NHCO2R3、N(phthaloyl)或NH2中选择，或者W进一步从(a)组中选择，其中J从OH或R中选择，P是适用于硝基还原酶或羧肽酶酶的底物基团。本发明还涉及使用通过本发明的方法制备的式(I)化合物作为癌症治疗的细胞毒素以及基因导向酶前药治疗(GDEPT)和抗体导向酶前药治疗(ADEPT)的前药。
• CYCLOPROPYLINDOLE COMPOUNDS AND THEIR USE AS PRODRUGS
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP0938474B1

  公开（公告）日：2005-11-23
• ANTIBODY-COMB POLYMER CONJUGATE
  申请人：UCB Pharma, S.A.

  公开号：EP1926757B1

  公开（公告）日：2012-02-22
• COMB POLYMERS
  申请人：UCB Pharma, S.A.

  公开号：EP1926757A1

  公开（公告）日：2008-06-04